|
1
|
Kubeček O, Laco J, Špaček J, Petera J,
Kopecký J, Kubečková A and Filip S: The pathogenesis, diagnosis,
and management of metastatic tumors to the ovary: A comprehensive
review. Clin Exp Metastasis. 34:295–307. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanna NN and Cohen AM: Ovarian neoplasms
in patients with colorectal cancer: Understanding the role of
prophylactic oophorectomy. Clin Colorectal Cancer. 3:215–222. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan KL, Tan WS, Lim JF and Eu KW:
Krukenberg tumors of colorectal origin: A dismal outcome-experience
of a tertiary center. Int J Colorectal Dis. 25:233–238. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fujiwara A, Noura S, Ohue M, Shingai T,
Yamada T, Miyashiro I, Ohigashi H, Yano M, Ishikawa O, Kamiura S
and Tomita Y: Significance of the resection of ovarian metastasis
from colorectal cancers. J Surg Oncol. 102:582–587. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McCormick CC, Giuntoli RL II, Gardner GJ,
Schulick RD, Judson K, Ronnett BM, Vang R and Bristow RE: The role
of cytoreductive surgery for colon cancer metastatic to the ovary.
Gynecol Oncol. 105:791–795. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rayson D, Bouttell E, Whiston F and Stitt
L: Outcome after ovarian/adnexal metastectomy in metastatic
colorectal carcinoma. J Surg Oncol. 75:186–192. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ojo J, De Silva S, Han E, Lin P,
Wakabayashi M, Nelson R and Lai LL: Krukenberg tumors from
colorectal cancer: presentation, treatment and outcomes. Am Surg.
77:1381–1385. 2011.PubMed/NCBI
|
|
8
|
Willmott F, Allouni KA and Rockall A:
Radiological manifestations of metastasis to the ovary. J Clin
Pathol. 65:585–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ganesh K, Shah RH, Vakiani E, Nash GM,
Skottowe HP, Yaeger R, Cercek A, Lincoln A, Tran C, Segal NH, et
al: Clinical and genetic determinants of ovarian metastases from
colorectal cancer. Cancer. 123:1134–1143. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Crobach S, Ruano D, van Eijk R, Fleuren
GJ, Minderhout I, Snowdowne R, Tops C, van Wezel T and Morreau H:
Target-enriched next-generation sequencing reveals differences
between primary and secondary ovarian tumors in formalin-fixed,
paraffin-embedded tissue. J Mol Diagn. 17:193–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
486:532–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murtaza M, Dawson SJ, Tsui DW, Gale D,
Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS,
et al: DNon-invasive analysis of acquired resistance to cancer
therapy by sequencing of plasma DNA. Nature. 497:108–112. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peeters M, Oliner KS, Parker A, Siena S,
Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, André T, Wiezorek
J, et al: Massively parallel tumor multigene sequencing to evaluate
response to panitumumab in a randomized phase III study of
metastatic colorectal cancer. Clin Cancer Res. 19:1902–1912. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang
F, Xu L and Yin R: Circulating tumor DNA is effective for the
detection of EGFR mutation in non-small cell lung cancer: A
meta-analysis. Cancer Epidemiol Biomarkers Prev. 24:206–212. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oxnard GR, Thress KS, Alden RS, Lawrance
R, Paweletz CP, Cantarini M, Yang JC, Barrett JC and Jänne PA:
Association between plasma genotyping and outcomes of treatment
with osimertinib (AZD9291) in advanced non-small-cell lung cancer.
J Clin Oncol. 34:3375–3382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Newman AM, Bratman SV, To J, Wynne JF,
Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, et
al: An ultrasensitive method for quantitating circulating tumor DNA
with broad patient coverage. Nat Med. 20:548–554. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Newman AM, Lovejoy AF, Klass DM, Kurtz DM,
Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, et al:
Integrated digital error suppression for improved detection of
circulating tumor DNA. Nat Biotechnol. 34:547–555. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu C, Ranjbar Nezami MR, Wu Z, DiCarlo J
and Wang Y: Detecting very low allele fraction variants using
targeted DNA sequencing and a novel molecular barcode-aware variant
caller. BMC Genomics. 18:52017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Narahara M, Higasa K, Nakamura S, Tabara
Y, Kawaguchi T, Ishii M, Matsubara K, Matsuda F and Yamada R:
Large-scale East-Asian eQTL mapping reveals novel candidate genes
for LD mapping and the genomic landscape of transcriptional effects
of sequence variants. PLoS One. 9:e1009242014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scherer F, Kurtz DM, Newman AM, Stehr H,
Craig AF, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, et
al: Distinct biological subtypes and patterns of genome evolution
in lymphoma revealed by circulating tumor DNA. Sci Transl Med.
8:364ra1552016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bokemeyer C, Bondarenko I, Makhson A,
Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G,
Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic
colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bazan V, Agnese V, Corsale S, Calò V,
Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G,
et al: Specific TP53 and/or Ki-ras mutations as independent
predictors of clinical outcome in sporadic colorectal
adenocarcinomas: Results of a 5-year Gruppo Oncologico dell'Italia
Meridionale (GOIM) prospective study. Ann Oncol. 16 Suppl
4:iv50–iv55. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kogita A, Yoshioka Y, Sakai K, Togashi Y,
Sogabe S, Nakai T, Okuno K and Nishio K: Inter- and intra-tumor
profiling of multi-regional colon cancer and metastasis. Biochem
Biophys Res Commun. 458:52–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shitara K, Yonesaka K, Denda T, Yamazaki
K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, et
al: Randomized study of FOLFIRI plus either panitumumab or
bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer
Sci. 107:1843–1850. 2016. View Article : Google Scholar : PubMed/NCBI
|
